Internal MedicineMar 11, 2021|2 min readBy DDNews StaffAeterna Zentaris initiates primary hypoparathyroidism preclinical programAeterna has obtained an exclusive license from The University of Sheffield to IP relating to parathyroid hormone fusion polypeptides